Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose

Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data

(2011) Rong Deng et al.   mAbs

Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies

(2010) Diane R. Mould et al.   BIODRUGS

An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation

(2010) B. Schoeberl et al.   CANCER RESEARCH

Population Pharmacokinetics of Therapeutic Monoclonal Antibodies

(2010) Nathanael L. Dirks et al.   CLINICAL PHARMACOKINETICS

ErbB receptors and signaling pathways in cancer

(2009) Nancy E Hynes et al.   CURRENT OPINION IN CELL BIOLOGY

Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site

(2009) J. Bostrom et al.   SCIENCE

Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor-PI3K Axis

(2009) B. Schoeberl et al.   Science Signaling

EGFR Antagonists in Cancer Treatment

(2008) Fortunato Ciardiello et al.   NEW ENGLAND JOURNAL OF MEDICINE